MX2025005209A - Compuestos lipídicos y usos de los mismos - Google Patents
Compuestos lipídicos y usos de los mismosInfo
- Publication number
- MX2025005209A MX2025005209A MX2025005209A MX2025005209A MX2025005209A MX 2025005209 A MX2025005209 A MX 2025005209A MX 2025005209 A MX2025005209 A MX 2025005209A MX 2025005209 A MX2025005209 A MX 2025005209A MX 2025005209 A MX2025005209 A MX 2025005209A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- lipid compounds
- tautomer
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos que tienen la siguiente estructura: (Ver compuesto (I)). o una sal farmacéuticamente aceptable, N-óxido, tautómero o estereoisómero del mismo, en donde R1, G1, W y m, n, o y p son como se definen en el presente documento. También se proporciona el uso de los compuestos como componente de formulaciones de nanopartículas lipídicas para la administración de un ácido nucleico, composiciones que comprenden los compuestos y métodos para su uso y preparación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263382389P | 2022-11-04 | 2022-11-04 | |
| US202363590756P | 2023-10-16 | 2023-10-16 | |
| PCT/IB2023/061006 WO2024095179A1 (en) | 2022-11-04 | 2023-11-01 | Lipid compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025005209A true MX2025005209A (es) | 2025-06-02 |
Family
ID=88731299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025005209A MX2025005209A (es) | 2022-11-04 | 2025-05-02 | Compuestos lipídicos y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250367129A1 (es) |
| EP (1) | EP4612129A1 (es) |
| JP (1) | JP2025538939A (es) |
| KR (1) | KR20250099738A (es) |
| CN (1) | CN120265611A (es) |
| AU (1) | AU2023375183A1 (es) |
| IL (1) | IL320338A (es) |
| MX (1) | MX2025005209A (es) |
| WO (1) | WO2024095179A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| WO2026088119A1 (en) | 2024-10-24 | 2026-04-30 | Pfizer Inc. | Lipidated tlr7/8 modulators as adjuvants and uses thereof |
| WO2026125590A1 (en) * | 2024-12-13 | 2026-06-18 | BioNTech SE | Measuring nucleic acid integrity |
| CN119613422B (zh) * | 2025-02-12 | 2025-08-22 | 北京引正基因科技有限公司 | 脂质化合物、包含其的组合物及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197553B1 (en) | 1994-07-15 | 2001-03-06 | Merck & Co., Inc. | Method for large scale plasmid purification |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| PL3908568T3 (pl) | 2019-01-11 | 2024-12-02 | Acuitas Therapeutics, Inc. | Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych |
| US12485181B2 (en) | 2019-06-28 | 2025-12-02 | Serina Therapeutics (Al), Inc. | Polyoxazoline-drug conjugates with novel pharmacokinetic properties |
| AU2021301922A1 (en) * | 2020-06-30 | 2023-02-02 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| WO2022032154A2 (en) | 2020-08-06 | 2022-02-10 | Modernatx, Inc. | Compositions for the delivery of payload molecules to airway epithelium |
| WO2023006062A1 (en) * | 2021-07-30 | 2023-02-02 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for mutant coronavirus |
-
2023
- 2023-11-01 IL IL320338A patent/IL320338A/en unknown
- 2023-11-01 WO PCT/IB2023/061006 patent/WO2024095179A1/en not_active Ceased
- 2023-11-01 US US19/125,013 patent/US20250367129A1/en active Pending
- 2023-11-01 CN CN202380081778.7A patent/CN120265611A/zh active Pending
- 2023-11-01 KR KR1020257018436A patent/KR20250099738A/ko not_active Withdrawn
- 2023-11-01 JP JP2025523831A patent/JP2025538939A/ja not_active Withdrawn
- 2023-11-01 AU AU2023375183A patent/AU2023375183A1/en active Pending
- 2023-11-01 EP EP23801901.2A patent/EP4612129A1/en active Pending
-
2025
- 2025-05-02 MX MX2025005209A patent/MX2025005209A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL320338A (en) | 2025-06-01 |
| KR20250099738A (ko) | 2025-07-02 |
| JP2025538939A (ja) | 2025-12-03 |
| WO2024095179A1 (en) | 2024-05-10 |
| AU2023375183A1 (en) | 2025-05-01 |
| US20250367129A1 (en) | 2025-12-04 |
| EP4612129A1 (en) | 2025-09-10 |
| CN120265611A (zh) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007720A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| MX2025002671A (es) | Lipidos para uso en formulaciones de nanoparticulas de lipidos | |
| WO2023114943A3 (en) | Lipids for use in lipid nanoparticle formulations | |
| WO2023114937A3 (en) | Fluorinated cationic lipids for use in lipid nanoparticles | |
| MX2025013218A (es) | Lipidos para usarse en formulaciones de nanoparticulas de lipido | |
| WO2019036008A8 (en) | Lipids for use in lipid nanoparticle formulations | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| EP4613741A3 (en) | Lipid nanoparticles for oligonucleotide delivery | |
| EP4420679A3 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| EP4410317A3 (en) | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| MX2025014915A (es) | Lipidos que contienen amida | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2025014916A (es) | Lípidos para usarse en nanopartículas lipídicas | |
| ZA202309527B (en) | Ionizable lipids and compositions for nucleic acid delivery | |
| WO2002074247A8 (en) | Pharmaceutical formulations for sustained release | |
| WO2006067614A3 (en) | Heteroaromatic derivatives useful as anticancer agents | |
| MX2025015196A (es) | Amida y éster mixtos que contienen lípidos para usarse en nanopartículas lipídicas | |
| ZA202403337B (en) | Lipid nanoparticles for oligonucleotide delivery | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| MX2022016263A (es) | Derivados de ciclobutil-urea. | |
| CR20210513A (es) | Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| ZA202200660B (en) | Process for the preparation of ridinilazole and crystalline forms thereof | |
| SE0402925D0 (sv) | Novel Compounds | |
| MX2025002166A (es) | Compuestos y metodos para modular her2 |